Unternehmen wird geladen
Just reported
Q3 2026 results
From Vertex Pharmaceuticals's results release of 2. November 2026; its quarterly report has since been filed.
Revenue
Actual
3,44B $
+12 % y/y
+3,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
2,56 $
-39 % y/y
-41 % q/qGuided
—
No guide given
Operating income, GAAP
Actual
712,9M $
-40 % y/y
-43 % q/qGuided
—
No guide given
Company outlook
Full year 2026
- Revenue13,15B $ – 13,25B $+10,0 % y/y Raised +0,4 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Vertex Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,5B $A+
EXELExelixis, Inc.17B $A+
JAZZJazz Pharmaceuticals plc15,4B $A
HALOHalozyme Therapeutics, Inc.11,5B $A+
TECHBIO-Techne Corp11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Womit das Unternehmen Geld verdient
- TRIKAFTA/KAFTRIO sales75 %
- ALYFTREK sales17 %
- KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI sales4 %
- CASGEVY sales2 %
- JOURNAVX sales2 %
Die Umsatzanteile sind Schätzungen für quarter ended June 30, 2026 und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
Was es verkauft5
ALYFTREK
A once-daily combination medicine that improves the function of the faulty protein that causes cystic fibrosis.
TRIKAFTA/KAFTRIO
A combination medicine that improves the function of the faulty protein that causes cystic fibrosis. TRIKAFTA and KAFTRIO are brand names used in different markets.
KALYDECO, ORKAMBI, and SYMDEKO/SYMKEVI
Other medicines for cystic fibrosis that improve the function of the protein involved in the disease.
2 weitere anzeigen
CASGEVY
A gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia. A patient's blood-forming cells are collected, edited at a manufacturing facility, and returned for infusion.
JOURNAVX
An oral, non-opioid medicine for moderate-to-severe acute pain in adults.
Wer es kauft5
- Specialty pharmacies and specialist distributors buy Vertex medicines and resell them to patients, pharmacies, health care providers, hospitals, or treatment centers.
- Major wholesalers in the United States buy Vertex medicines for resale through pharmacies and health care providers.
- Outside the United States, distributors, retail pharmacies, hospitals, and clinics buy or distribute medicines; some hospitals and clinics are government-owned or supported.
2 weitere anzeigen
- Authorized treatment centers can receive CASGEVY directly from Vertex in some markets.
- Government health programs and commercial insurers decide whether to cover medicines and reimburse purchases.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1The business depends substantially on cystic fibrosis medicines; sales therefore depend on continued patient use, access, and the medicines' ability to compete with other treatments.
- 2Vertex relies on outside manufacturers and suppliers for much of its commercial and clinical supply. CASGEVY also requires coordinated cell collection, editing, shipping, and treatment-center infusion.
- 3Sales depend on government programs and commercial insurers covering medicines and agreeing to reimbursement terms. The company also pays royalties on certain cystic fibrosis medicines and shares CASGEVY profits with CRISPR Therapeutics.
Was schiefgehen könnte
- 1The company identifies its cystic fibrosis medicines as a substantial source of business dependence. Competing treatments, changes in patient use, or loss of patent protection could reduce sales.
- 2Vertex's future products depend on clinical trials showing acceptable safety and benefit and on regulators approving them. A delay or failure in programs such as povetacicept, inaxaplin, or zimislecel could limit its ability to add new medicines.
- 3The company relies on complex supply chains, outside manufacturers, and treatment-center coordination, particularly for cell and gene therapies. Manufacturing or distribution problems could delay or interrupt supply.
Über Vertex Pharmaceuticals Inc.
Vertex discovers, tests, manufactures, and sells prescription medicines. Its approved medicines treat cystic fibrosis, severe sickle cell disease, transfusion-dependent beta thalassemia, and moderate-to-severe acute pain; it is also testing treatments for kidney disease, type 1 diabetes, and other conditions. It sells mainly through specialty pharmacies, distributors, and wholesalers, with some gene therapy supplied directly to treatment centers.
- Hauptsitz
- Boston, Massachusetts
- Gegründet
- 1989
- Beschäftigte
- 6,400 (December 31, 2025, high)
- Notiert an
- NASDAQ
- Geschäftsjahresende
- December 31
Gebaut aus den eigenen Einreichungen von Vertex Pharmaceuticals Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.